JP2016526920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526920A5 JP2016526920A5 JP2016533383A JP2016533383A JP2016526920A5 JP 2016526920 A5 JP2016526920 A5 JP 2016526920A5 JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016526920 A5 JP2016526920 A5 JP 2016526920A5
- Authority
- JP
- Japan
- Prior art keywords
- replication competent
- recombinant replication
- competent retrovirus
- retrovirus
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001430294 unidentified retrovirus Species 0.000 claims 90
- 229920000023 polynucleotide Polymers 0.000 claims 39
- 239000002157 polynucleotide Substances 0.000 claims 39
- 150000007523 nucleic acids Chemical class 0.000 claims 34
- 230000001177 retroviral Effects 0.000 claims 33
- 108020004707 nucleic acids Proteins 0.000 claims 28
- 239000002773 nucleotide Substances 0.000 claims 24
- 125000003729 nucleotide group Chemical group 0.000 claims 24
- 210000004027 cells Anatomy 0.000 claims 23
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 22
- 241001663880 Gammaretrovirus Species 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 230000002062 proliferating Effects 0.000 claims 10
- 241000714177 Murine leukemia virus Species 0.000 claims 9
- 241000700605 Viruses Species 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 6
- 230000003308 immunostimulating Effects 0.000 claims 6
- 241000714165 Feline leukemia virus Species 0.000 claims 5
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004962 mammalian cells Anatomy 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrugs Drugs 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 102000000311 EC 3.5.4.1 Human genes 0.000 claims 4
- 108010080611 EC 3.5.4.1 Proteins 0.000 claims 4
- 206010017758 Gastric cancer Diseases 0.000 claims 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025650 Malignant melanoma Diseases 0.000 claims 4
- 241000713869 Moloney murine leukemia virus Species 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 102000030819 Purine-Nucleoside Phosphorylase Human genes 0.000 claims 4
- 108091022020 Purine-Nucleoside Phosphorylase Proteins 0.000 claims 4
- 241000712909 Reticuloendotheliosis virus Species 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 4
- 210000001635 Urinary Tract Anatomy 0.000 claims 4
- 206010046766 Uterine cancer Diseases 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 201000005216 brain cancer Diseases 0.000 claims 4
- 201000011231 colorectal cancer Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 230000003000 nontoxic Effects 0.000 claims 4
- 231100000252 nontoxic Toxicity 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 210000001519 tissues Anatomy 0.000 claims 4
- 230000035897 transcription Effects 0.000 claims 4
- 108020004388 MicroRNAs Proteins 0.000 claims 3
- 102000008187 gag Gene Products Human genes 0.000 claims 3
- 108010060555 gag Gene Products Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 229920001239 microRNA Polymers 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 claims 3
- 102000007991 pol Gene Products Human genes 0.000 claims 3
- 108010089520 pol Gene Products Proteins 0.000 claims 3
- 238000010839 reverse transcription Methods 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 241000282324 Felis Species 0.000 claims 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N Flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 229940047122 Interleukins Drugs 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 241001504519 Papio ursinus Species 0.000 claims 2
- 241000881705 Porcine endogenous retrovirus Species 0.000 claims 2
- 230000025458 RNA interference Effects 0.000 claims 2
- -1 RNAi Proteins 0.000 claims 2
- 229920001785 Response element Polymers 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 108020004459 Small Interfering RNA Proteins 0.000 claims 2
- 241000713820 Squirrel monkey retrovirus Species 0.000 claims 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims 2
- 108020004440 Thymidine Kinase Proteins 0.000 claims 2
- 241000101098 Xenotropic MuLV-related virus Species 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 229960004413 flucytosine Drugs 0.000 claims 2
- 201000010915 glioblastoma multiforme Diseases 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000006011 modification reaction Methods 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 230000001613 neoplastic Effects 0.000 claims 2
- 230000001105 regulatory Effects 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 230000002588 toxic Effects 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 231100000167 toxic agent Toxicity 0.000 claims 2
- 239000003440 toxic substance Substances 0.000 claims 2
- 241001485018 Baboon endogenous virus Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102100018054 PTBP1 Human genes 0.000 claims 1
- 101700069057 PTBP1 Proteins 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
Claims (96)
レトロウイルスGAGタンパク質;
レトロウイルスPOLタンパク質;
レトロウイルスエンベロープ;
レトロウイルスポリヌクレオチドであって、レトロウイルスポリヌクレオチド配列の3'末端に長末端反復(LTR)配列、レトロウイルスポリヌクレオチドの5'末端に哺乳動物の細胞における発現に適しているプロモーター配列、gag核酸ドメイン、pol核酸ドメイン及びenv核酸ドメインを含む前記レトロウイルスポリヌクレオチド;
IRESの分岐領域においてAバルジの6A'sからなる内部リボソーム侵入部位(IRES)を含むカセットであって、前記IRESが異種ポリヌクレオチドに機能可能に連結されており、前記カセットが3'LTRの5'側、及びレトロウイルスエンベロープをコードするenv核酸ドメインの3'側に位置するカセット;並びに
標的細胞における逆転写、パッケージング及び組み込みのために必要なシス作用性配列を含み、
RCRが配列番号21を含むベクター(pACE)と比較して、6回の継代後に高い複製能を維持する、上記組換え複製コンピテントレトロウイルス。 A recombinant replication competent retrovirus comprising:
Retroviral GAG protein;
Retroviral POL protein;
Retroviral envelope;
A retroviral polynucleotide, a long terminal repeat (LTR) sequence at the 3 ′ end of the retroviral polynucleotide sequence, a promoter sequence suitable for expression in mammalian cells at the 5 ′ end of the retroviral polynucleotide, a gag nucleic acid Said retroviral polynucleotide comprising a domain, a pol nucleic acid domain and an env nucleic acid domain;
A cassette containing an internal ribosome entry site (IRES) consisting of 6A's of A bulge in the IRES branch region, wherein the IRES is operably linked to a heterologous polynucleotide, and the cassette is 5 'to the 3'LTR. And a cassette located 3 ′ of the env nucleic acid domain encoding the retroviral envelope; and cis-acting sequences necessary for reverse transcription, packaging and integration in the target cell,
The above-mentioned recombinant replication competent retrovirus, which maintains high replication ability after 6 passages compared to a vector (pACE) in which the RCR contains SEQ ID NO: 21.
レトロウイルスGAGタンパク質;
レトロウイルスPOLタンパク質;
レトロウイルスエンベロープ;
レトロウイルスポリヌクレオチドであって、レトロウイルスポリヌクレオチド配列の3'末端に長末端反復(LTR)配列、レトロウイルスポリヌクレオチドの5'末端に哺乳動物の細胞における発現に適しているプロモーター配列、gag核酸ドメイン、pol核酸ドメイン及びenv核酸ドメインを含む前記レトロウイルスポリヌクレオチド;
(i)異種ポリヌクレオチドに機能可能に連結された最小内部リボソーム侵入部位(IRES)、(ii)miRNAに連結されたpolIIIプロモーター、又は(iii)(ii)に先行するか又は続く異種ポリヌクレオチドに機能可能に連結されたミニプロモーターを含むカセットであって、3'LTRの5'側、及びレトロウイルスエンベロープをコードするenv核酸ドメインの3'側に位置するカセット;及び
標的細胞における逆転写、パッケージング及び組み込みのために必要なシス作用性配列;
を含む、上記組換え複製コンピテントレトロウイルス。 A recombinant replication competent retrovirus comprising:
Retroviral GAG protein;
Retroviral POL protein;
Retroviral envelope;
A retroviral polynucleotide, a long terminal repeat (LTR) sequence at the 3 ′ end of the retroviral polynucleotide sequence, a promoter sequence suitable for expression in mammalian cells at the 5 ′ end of the retroviral polynucleotide, a gag nucleic acid Said retroviral polynucleotide comprising a domain, a pol nucleic acid domain and an env nucleic acid domain;
(I) a minimal internal ribosome entry site (IRES) operably linked to a heterologous polynucleotide, (ii) a polIII promoter linked to a miRNA, or (iii) a heterologous polynucleotide preceding or following (ii) A cassette comprising a operably linked mini-promoter, located 5 ′ of the 3 ′ LTR and 3 ′ of the env nucleic acid domain encoding the retroviral envelope; and reverse transcription, packaging in the target cell Cis-acting sequences required for binding and integration;
A recombinant replication competent retrovirus comprising the above.
(i)配列番号41と95%の同一性を有し、J-K分岐領域に5A'sを有する配列; (I) a sequence having 95% identity with SEQ ID NO: 41 and having 5A's in the JK branch region;
(ii)分岐領域に5A'sを含む配列番号41に記載の配列を含み、配列番号41の塩基対1の後から約塩基183の任意の箇所から始まり、544まで続く、トランケートされたIRES (Ii) a truncated IRES comprising the sequence set forth in SEQ ID NO: 41 containing 5A's in the branching region, starting from any position of about base 183 after base pair 1 of SEQ ID NO: 41 and continuing to 544
(iii)配列番号41の約123から544又は約183から544に記載の配列を含み、J-K分岐領域のA-バルジに5個のAを有し、分岐領域に7個のAを有する同様のIRESに対して改善された安定性を有するトランケートされたIRES; (Iii) comprising the sequence of SEQ ID NO: 41 of about 123 to 544 or about 183 to 544, having 5 A in the A-bulge of the JK branch region and 7 A in the branch region Truncated IRES with improved stability against IRES;
(iv)J-K分岐領域のA-バルジに5個のAを有する配列番号41に記載の配列、及び (Iv) the sequence of SEQ ID NO: 41 having 5 A's in the A-bulge of the J-K branch region, and
(v)TがUであり得る上記のいずれか (V) any of the above where T can be U
からなる群から選択される配列を含む、請求項1に記載の操作された核酸。2. The engineered nucleic acid of claim 1 comprising a sequence selected from the group consisting of:
レトロウイルスGAGタンパク質; Retroviral GAG protein;
レトロウイルスPOLタンパク質; Retroviral POL protein;
レトロウイルスエンベロープ; Retroviral envelope;
レトロウイルスポリヌクレオチドであって、レトロウイルスポリヌクレオチド配列の3'末端に長末端反復(LTR)配列、レトロウイルスポリヌクレオチドの5'末端に哺乳動物の細胞における発現に適しているプロモーター配列、gag核酸ドメイン、pol核酸ドメイン及びenv核酸ドメインを含む前記レトロウイルスポリヌクレオチド; A retroviral polynucleotide, a long terminal repeat (LTR) sequence at the 3 ′ end of the retroviral polynucleotide sequence, a promoter sequence suitable for expression in mammalian cells at the 5 ′ end of the retroviral polynucleotide, a gag nucleic acid Said retroviral polynucleotide comprising a domain, a pol nucleic acid domain and an env nucleic acid domain;
IRESの分岐領域においてAバルジの5又は6A'sからなる内部リボソーム侵入部位(IRES)を含むカセットであって、前記IRESが異種ポリヌクレオチドに機能可能に連結されており、前記カセットが3'LTRの5'側、及びレトロウイルスエンベロープをコードするenv核酸ドメインの3'側に位置するカセット;並びに A cassette containing an internal ribosome entry site (IRES) consisting of 5 or 6 A's of A bulge in the branch region of IRES, wherein said IRES is operably linked to a heterologous polynucleotide, and said cassette is 5 'of 3'LTR A cassette located on the 'side and 3' on the env nucleic acid domain encoding the retroviral envelope; and
標的細胞における逆転写、パッケージング及び組み込みのために必要なシス作用性配列を含む、 Contains cis-acting sequences necessary for reverse transcription, packaging and integration in target cells,
上記組換え複製コンピテントレトロウイルス。 The above recombinant replication competent retrovirus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361862433P | 2013-08-05 | 2013-08-05 | |
US61/862,433 | 2013-08-05 | ||
PCT/US2014/049831 WO2015021077A1 (en) | 2013-08-05 | 2014-08-05 | Recombinant vector with optimized a-bulge |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016526920A JP2016526920A (en) | 2016-09-08 |
JP2016526920A5 true JP2016526920A5 (en) | 2017-09-14 |
Family
ID=52461883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016533383A Pending JP2016526920A (en) | 2013-08-05 | 2014-08-05 | Recombinant vector with optimized A-bulge |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3030659A4 (en) |
JP (1) | JP2016526920A (en) |
CN (1) | CN105579581A (en) |
AU (1) | AU2014306093A1 (en) |
CA (1) | CA2920049A1 (en) |
WO (1) | WO2015021077A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
US20210047425A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
WO2022165001A1 (en) | 2021-01-29 | 2022-08-04 | Merck Sharp & Dohme Llc | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
TW202332694A (en) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | Serum half-life extended pd-l1 binding polypeptides |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4937190A (en) * | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
US20050260568A1 (en) * | 2004-04-30 | 2005-11-24 | Min Gao | Hepatitis C virus assays |
JP5684130B2 (en) * | 2008-09-26 | 2015-03-11 | トカジェン インコーポレーテッド | Recombinant vector |
US8829173B2 (en) * | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
US20110020814A1 (en) * | 2009-06-05 | 2011-01-27 | Ipierian, Inc. | Methods and compositions for selection of stem cells |
ES2718546T3 (en) * | 2009-06-17 | 2019-07-02 | Tocagen Inc | Producing cells for competent replication retroviral vectors |
-
2014
- 2014-08-05 CA CA2920049A patent/CA2920049A1/en not_active Abandoned
- 2014-08-05 JP JP2016533383A patent/JP2016526920A/en active Pending
- 2014-08-05 WO PCT/US2014/049831 patent/WO2015021077A1/en active Application Filing
- 2014-08-05 EP EP14835030.9A patent/EP3030659A4/en not_active Withdrawn
- 2014-08-05 AU AU2014306093A patent/AU2014306093A1/en not_active Abandoned
- 2014-08-05 CN CN201480053358.9A patent/CN105579581A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016526920A5 (en) | ||
ES2779149T3 (en) | Retroviral vector that has immunostimulatory activity | |
US11279949B2 (en) | Recombinant vectors comprising 2A peptide | |
EP2909324B1 (en) | Retroviral vector with mini-promoter cassette | |
ES2911448T3 (en) | Combined Vectors and Methods for Cancer Treatment | |
CN1058993C (en) | Preparation method and application of molecular chimera for treating cancer | |
JP2012503986A5 (en) | ||
US11788101B2 (en) | Genomic insulator elements and uses thereof | |
JP2012503987A5 (en) | ||
JP2015533510A5 (en) | ||
JP2024045608A (en) | Vector system for expressing regulatory RNA | |
JP2019503653A5 (en) | ||
Ku et al. | Lentiviral vector induces high-quality memory T cells via dendritic cells transduction | |
TWI817997B (en) | Chimeric antigen receptors that bind to ssea4 and uses thereof | |
JP2023503858A (en) | 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA) Medical Use | |
ABAAN et al. | Gene therapy in human breast cancer | |
Weber et al. | Retroviral vectors | |
US11970708B2 (en) | Gene therapy vector with minimizing recombination, recombinant retrovirus comprising the vector, and pharmaceutical composition for preventing or treating cancer comprising the recombinant retrovirus | |
RU2697797C2 (en) | Genetic construct for inducing proliferation of peripheral monocytes in vitro | |
EP4249596A1 (en) | New gene recombinant vaccinia virus and utilization thereof | |
CN1162643A (en) | Preparation and usage of molecular chimera for curing cancer | |
WO2018073307A1 (en) | Mlv-based gene therapy with mutated integrase coupled to peptides |